Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Status:
Active, not recruiting
Trial end date:
2021-11-05
Target enrollment:
Participant gender:
Summary
Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib
may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib
monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.